NCT06607367View on ClinicalTrials.gov

REscuing Bone Marrow Function in Patients with AplaStic AnaEmia and Bone Marrow FaiLure Post AllogEneiC Transplantation 2

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 30, 2024

Primary Completion Date

October 30, 2025

Study Completion Date

October 30, 2026

Conditions
Poor Graft FunctionAplastic Anemia Idiopathic
Interventions
DRUG

Ruxolitinib (JAKAVI®)

Initial starting dose will be 10mg BD

DRUG

Eltrombopag (Revolade®)

Initial starting dose will be 50mg daily

Trial Locations (1)

3050

The Royal Melbourne Hospital, Parkville

Sponsors

Lead Sponsor

Melbourne Health
All Listed Sponsors
lead

Melbourne Health

OTHER

NCT06607367 - REscuing Bone Marrow Function in Patients with AplaStic AnaEmia and Bone Marrow FaiLure Post AllogEneiC Transplantation 2 | Biotech Hunter | Biotech Hunter